Recently, the Centers for Medicare & Medicaid Services (CMS) included Novo Nordisk’s key GLP-1 drugs, Ozempic and Wegovy, in its list of 15 drugs for Medicare price negotiations. This announcement ...

According to Novo Nordisk, over 40% of persons with type 2 diabetes have chronic renal disease, which affects roughly 37 million adults in the United States. Last year, the FDA authorized Wegovy ...

Novo Nordisk said the Food and Drug Administration ... The FDA approved semaglutide for weight loss under the brand name Wegovy in 2021. The European Union's drug regulator has already thrown ...

That includes Ozempic, its weight loss counterpart Wegovy and another diabetes treatment called Rybelsus. The FDA's decision also comes as Novo Nordisk faces increased competition from Eli ...

Last year, the FDA had approved the use of Wegovy for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. Novo Nordisk is also testing its GLP-1 ...

Wegovy is Novo Nordisk's flagship obesity drug while Ozempic is its diabetes treatment. The trial was conducted on 125 overweight or obese patients and the most common side effects were ...